Instruction for use: Selegiline

Dosage form: tablets

Active substance: Selegiline*

ATX

N04BD01 Selegiline

Pharmacological groups:

Dopaminomimetics

Anti-Parkinsonics

The nosological classification (ICD-10)

G20 Parkinson's disease: A trembling paralysis; Idiopathic Parkinsonism; Parkinson's disease; Symptomatic Parkinsonism

G21 Secondary Parkinsonism: Medicinal Parkinsonism; Parkinsonism; Parkinsonism symptomatic; Disorders of extrapyramidal system; Parkinson's Syndrome

Composition and release form

1 tablet contains selegiline hydrochloride 5 mg; In blistere 10 pcs., In a cardboard bundle 5 blisters.

Pharmachologic effect

Mode of action - antiparkinsonian.

Inhibits MAO type B and increases the content of dopamine (and other tyramine-like substances) in the synapses of various parts of the brain, incl. Nuclei of the extrapyramidal system.

Indication of the drug Selegiline

Parkinson's disease, Parkinsonism.

Contraindications

Hypersensitivity.

Application in pregnancy and breastfeeding

When appointing pregnant and lactating mothers, risk and therapeutic benefit should be compared.

Side effects

Decrease AD, nausea, confusion, psychosis.

Interaction

Strengthens and lengthens the effect of levodopa.

Dosing and Administration

Inside, starting with 1 tab. In the morning (together with breakfast); With insufficient effect, the dose is increased to 2 tablets. per day.

Overdose

Symptoms are agitation and involuntary movements that disappear when the dose is lowered.

Precautionary measures

Caution is prescribed for cardiovascular, endocrine diseases, gastrointestinal disorders, impaired renal function, glaucoma.

Storage conditions of the drug Selegiline

In a dry place, at a temperature below 25 ° C.

Keep out of the reach of children.

Shelf life of the drug Selegiline

3 years.

Do not use after the expiry date printed on the package.